Company Name : Jagsonpal Pharmaceutical Ltd
Address : T-210 J, Shahpur Jat, New Delhi – 110 049, India
Tel No: 91 11 2649 4519
Email : india@jagsonpalpharma.com
Website : http://www.jagsonpal.com/
Company Profile
Jagsonpal is among India’s premiere pharmaceutical companies. The firm recorded sales revenues of $37 million in the year 2011. Jagsonpal has substantial research and development, manufacturing, marketing and distribution facilities. An impeccable track record of growth and profitability spanning over 4 decades, makes Jagsonpal an ideal company to partner with.
Founded in 1964 the company specializes in developing and manufacturing bulk drugs and pharmaceutical formulations. Over the past 40 years the firm has grown by leaps and bounds. The firm is committed to sustainable growth and is aggressively pursuing growth through market penetration, market expansion and multi-national expansion.
Jagsonpal is ranked 68th in the Indian pharmaceutical industry. The industry is comprised of over 28,000 manufacturing units putting Jagsonpal in the ivy league of the Indian Pharmaceutical companies. The firm’s objective is to increase market share and become a dominant player in the Indian Pharmaceutical Industry.
Jagsonpal has an expanding international portfolio of affiliates, joint ventures and representative offices across the globe making it a truly international operation. The firm is represented by 2,500 agents worldwide and has offices in 3 continents. The company’s operations span Russia, Brazil, USA, Ukraine, Sri Lanka, Cameroon, Thailand, Argentina, Germany, Switzerland, Korea, Egypt and Vietnam making Jagsonpal’s reach truly global.
Pearson Syndrome is an extremely rare condition and the prevalence is approximately 1 in a…
A striking 90% of the 3000 Diabetologists and Endocrinologists surveyed, emphasised the importance of continuous…
People who smoke are also at much higher risk of developing diabetes compared to non-smokers…
17th edition of CPHI& PMEC India Expo to be held from 26th November-28thNovember 2024, at the India…
Lonavala, November 12, 2024: As the global cancer burden rises to 30 million cases by…
The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…